This is the fact the category tends to skip past.
Cannabis does not have an enzyme that makes CBN. There is no CBNA synthase. CBN forms when THC sits in contact with oxygen, warmth and light, and the terpene ring aromatizes. Old, badly stored cannabis has high CBN because its THC has broken down. Heating cannabis produces CBN too. In one 2022 analysis, 17.2 percent of delta-9 THC degraded in a gas chromatograph inlet, generating CBN.
Practically, this means CBN content in a hemp product is a marker of what has happened to the material rather than a marker of intentional cultivation. Concentrated CBN products are made by deliberately degrading THC or by synthesis.
CBD is the opposite. The plant builds CBDA through a dedicated enzyme, and CBD is what CBDA becomes when heated.
CBN is a weak, low-efficacy partial agonist at CB1. A 2025 study in Neuropsychopharmacology measured pEC50 5.4 with a maximum effect of 29 percent, against THC’s pEC50 6.4 and 72 percent. Older work using a different assay reported an EC50 around 0.12 micromolar, roughly thirty times more potent. Both are legitimate measurements from different systems, which is a useful reminder that single numbers quoted without their assay context are not very meaningful.
The more interesting finding in that 2025 paper concerns CBN’s metabolite. 11-hydroxy-CBN reaches brain concentrations equivalent to CBN itself, and it is a CB1 partial agonist with potency and efficacy comparable to THC: pEC50 6.0, maximum effect 75 percent. So if CBN does anything centrally, its metabolite is probably doing much of the work.
That also creates a theoretical route to intoxication at high oral doses, which is why the honest answer to “is CBN psychoactive” is “weakly, at doses far above what anyone sells.”
CBN’s most potent measured action is at TRPA1, a sensory ion channel, with an EC50 of 0.18 micromolar. It is a TRPM8 antagonist at 0.21 micromolar. At CB2 it is negligible.
CBD, as covered elsewhere on this site, works mainly outside the cannabinoid receptor system altogether.
CBN is marketed almost exclusively for sleep. It is worth understanding where that idea came from, because it did not come from research.
The reasoning ran like this. Aged cannabis has a reputation for being sedating. Aged cannabis has high CBN. Therefore CBN is sedating. That is a confound, not a finding. Aged cannabis differs from fresh cannabis in many ways, including substantial terpene loss and reduced THC.
A secondary source of confusion is 1970s literature describing nabilone as a “potent antiemetic cannabinol.” Nabilone is a synthetic THC analogue. It is not CBN.
Rat polysomnography does show CBN increasing total sleep time, with the effect apparently driven substantially by the 11-OH-CBN metabolite. That is genuine science. It is also a rat.
There is no evidence at consumer doses, and it is not obvious why anyone should expect an effect there.
If your interest is sleep specifically, neither compound has adequate human evidence at consumer doses. CBD has no adequate sleep trial base at all, and drowsiness appears in the epilepsy trials as a side effect rather than a benefit. CBN has one trial that missed its primary endpoint at a dose sixty times higher than what is sold.
We would rather tell you that than sell you a story. If you want to try CBN, look at the actual milligram content and understand that you are well below any studied dose.
Still weighing up the options? See CBN vs CBC, CBG vs CBN or CBD vs melatonin. Endoca products related to this comparison: CBN products and CBD for sleep products.
CBN derived from hemp has been treated as lawful under the 2018 Farm Bill on the same basis as CBD, provided the source material stays under 0.3 percent delta-9 THC by dry weight.
CBN’s position becomes less comfortable from 12 November 2026. Section 781 of Public Law 119-37 excludes cannabinoids that are synthesized or manufactured outside the plant. Because concentrated CBN is generally produced by deliberately converting THC rather than by extraction of naturally occurring CBN, some CBN products may fall within that exclusion. FDA has not yet published the cannabinoid lists that would settle this, more than six months past its deadline. Anyone selling or buying concentrated CBN should watch this closely.
CBN has no published human pharmacokinetic data. The 2026 trial recorded 247 mild to moderate adverse events across its arms at 30 mg and 300 mg.
CBD’s profile is better characterized, including liver enzyme elevations at therapeutic doses and cytochrome P450 inhibition.
CBN appears on every Endoca certificate of analysis, and we report it whether or not it flatters the product, because in a full-spectrum extract CBN content tells you something real about how the material was handled. Low CBN in a CBD product is a sign of good storage and fresh extraction. That is a quality signal, and it is the opposite of the signal a CBN-marketed product is trying to send.
The first controlled trial in people with insomnia did not find a significant effect on time spent awake at night, at either 30 mg or 300 mg. Some secondary measures improved at 300 mg.
Weakly, and only at doses far above what is sold. Its metabolite is a THC-strength CB1 agonist, which is the mechanism of concern.
Usually a fraction of a percent, and it rises as the product ages.
It occurs naturally as a breakdown product. Concentrated CBN in products is typically produced deliberately from THC.
Neither has adequate evidence at consumer doses. We would rather say so.
Many products combine them, and both are found together in full-spectrum hemp extracts. There is no human trial showing the combination works better for sleep than either one alone.
They are not comparable on a single scale. CBN acts weakly on the CB1 receptor, while CBD barely binds to it at all and works through other routes. Stronger depends on which effect you measure.
Lavender I et al. The effects of cannabinol on sleep in insomnia disorder. J Sleep Res 2026;35:e70284.
Arnold JC et al. Cannabinol and its metabolite 11-OH-CBN in sleep. Neuropsychopharmacology 2025;50:586-595.
Corroon J. Cannabinol and Sleep: Separating Fact from Fiction. Cannabis Cannabinoid Res 2021;6:366-371.
De Petrocellis L et al. Effects of cannabinoids on TRP channels. Br J Pharmacol 2011;163:1479-1494.
Garcia-Valverde MT et al. Thermal degradation of cannabinoids. Front Chem 2022;10:1038729.
Husni AS et al. Evaluation of phytocannabinoids at CB1 and CB2. Med Chem Res 2014.
Congressional Research Service. Legal Sidebar LSB11381, updated 22 December 2025.
Last reviewed 1 September 2026.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.